A major achievement with far-reaching implications for treating deadly skin cancer has been discovered by Tel Aviv University ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Jazz Pharmaceuticals plc looks very undervalued at 2.4x sales as oncology catalysts (Ziihera, Zepzelca, Epidiolex) drive ...

There's no coming back from death, but that doesn't mean that all of you goes at the same time, some parts linger on for days ...

STAYING with a friend recently, above my bed hung what I at first took to be a piece of felted art. On touching it however I found it was a peel ...

EpiBiologics launched in 2023 with a $50 million series A, having been founded to take forward the work of renowned antibody ...

There are factors that can hinder this natural cell renewal process, such as aging, sun exposure, inflammation, dehydration, and disruption of the skin barrier. To support the skin's natural cell ...

Low-dose megestrol enhances hormone therapy for ER-positive breast cancer, reducing tumor proliferation and improving ...

RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to severe alopecia areata (AA) in at least 500 subjects. -- Cinainu is the first topical ...

US FDA & CDE in China grants breakthrough therapy designation to Bayer’s sevabertinib as a first-line treatment for patients with HER2-mutant NSCLC: Berlin Wednesday, January 7, ...

HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the ...

The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...